Literature DB >> 9306966

Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network.

R Montironi1, L Diamanti, R Pomante, D Thompson, P H Bartels.   

Abstract

The aim of this paper was to test the usefulness of a Bayesian belief network (BBN) as a decision support system in the uncertainty assessment of benign prostatic tissue, either associated or not with inflammation or adjacent to prostatic adenocarcinoma (PAC) or prostatic intraepithelial neoplasia (PIN). A shallow network was used with eight first-level descendant nodes for the diagnostic clues, each independently linked by a conditional probability matrix to a root node containing the diagnostic alternatives. One diagnostic evidence node was based on the tissue architecture and the others were based on cell features. The efficacy of the network was tested on a series of 45 simple prostatectomy specimens, subdivided as follows; benign prostatic tissue not associated with other diseases (15 cases), associated with acute and/or chronic inflammation (15 cases), and adjacent to accidentally discovered PAC or PIN (15 cases). The highest belief values for the diagnostic alternative normal prostate (NP) were obtained in the 15 cases not associated with other diseases, the mean value being 0.996. The 15 cases evaluated in areas with inflammation showed the lowest belief values for NP (mean 0.774). For the 15 cases evaluated in specimens with PAC or PIN, the belief values for NP were intermediate between those from normal prostatic tissue associated with inflammation and those not associated (mean 0.925). Moreover, it was found that subtle changes were also present at a certain distance from the tumour. In conclusion, the network can be used as a decision support system to differentiate with high certainty benign prostate adjacent to PAC or PIN from benign prostatic tissue either associated or not with inflammation. The subtle morphological alteration detected with the BBN may be considered malignancy-associated changes.

Entities:  

Mesh:

Year:  1997        PMID: 9306966     DOI: 10.1002/(SICI)1096-9896(199708)182:4<442::AID-PATH866>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  Shared gene expression alterations in prostate cancer and histologically benign prostate from patients with prostate cancer.

Authors:  Farhad Kosari; John C Cheville; Cristiane M Ida; R Jeffrey Karnes; Alexey A Leontovich; Thomas J Sebo; Sibel Erdogan; Erika Rodriguez; Stephen J Murphy; George Vasmatzis
Journal:  Am J Pathol       Date:  2012-05-26       Impact factor: 4.307

2.  Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology.

Authors:  Ryan L Parr; Gabriel D Dakubo; Keith A Crandall; Jennifer Maki; Brian Reguly; Andrea Aguirre; Roy Wittock; Kerry Robinson; Jude S Alexander; Mark A Birch-Machin; Mamdouh Abdel-Malak; M Kent Froberg; Eleftherios P Diamandis; Robert E Thayer
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

Review 3.  The awakening of an advanced malignant cancer: an insult to the mitochondrial genome.

Authors:  Cody C Cook; Masahiro Higuchi
Journal:  Biochim Biophys Acta       Date:  2011-09-02

4.  Diagnostic distance of high grade prostatic intraepithelial neoplasia from normal prostate and adenocarcinoma.

Authors:  R Montironi; R Pomante; P Colanzi; D Thompson; P W Hamilton; P H Bartels
Journal:  J Clin Pathol       Date:  1997-09       Impact factor: 3.411

5.  Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer.

Authors:  Sachin Bhusari; Bing Yang; Jessica Kueck; Wei Huang; David F Jarrard
Journal:  Prostate       Date:  2011-03-22       Impact factor: 4.104

Review 6.  Evidence for field cancerization of the prostate.

Authors:  Larisa Nonn; Vijayalakshmi Ananthanarayanan; Peter H Gann
Journal:  Prostate       Date:  2009-09-15       Impact factor: 4.104

7.  Markers of field cancerization: proposed clinical applications in prostate biopsies.

Authors:  Kristina A Trujillo; Anna C Jones; Jeffrey K Griffith; Marco Bisoffi
Journal:  Prostate Cancer       Date:  2012-05-14

8.  Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors.

Authors:  Uma R Chandran; Rajiv Dhir; Changqing Ma; George Michalopoulos; Michael Becich; John Gilbertson
Journal:  BMC Cancer       Date:  2005-05-13       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.